Conversión de tuberculina en pacientes reumatológicos durante terapia biológica. Infección reciente o tuberculosis latente oculta

Javier Iván Lasso Apráez, MD.


Raval A, Akhavan-Toyserkani G, Brinker A, Avigan M. Brief communication: characteristics of spontaneous cases of tuberculosis associated with infliximab. Ann Intern Med. 2007;147:699.

Westhovens R, Yocum D, Han J, Berman A, Strusberg I, Geusens P. The safety of infliximab, combined with background treatments, among patients with rheumatoid arthritis and various comorbidities: a large, randomized, placebo-controlled trial. Arthritis Rheum. 2006;54:1075.

Hsia EC, Cush JJ, Matteson EL, Beutler A, Doyle MK, Hsu B. Comprehensive tuberculosis screening program in patients with inflammatory arthritis treated with golimumab, a human anti-tumor necrosis factor antibody, in Phase III clinical trials. Arthritis Care Res (Hoboken). 2013;65:309.

Chen DY, Shen GH, Chen YM, Chen HH, Hsieh CW, Lan JL. Biphasic emergence of active tuberculosis in rheumatoid arthritis patients receiving TNF alpha inhibitors: the utility of IFN gamma assay. Ann Rheum Dis. 2012;71:231.

Keane J, Gershon S, Wise RP, Mirabile-LevensE, KasznicaJ, Schwieterman WD, et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med. 2001;345:1098.

Tuberculosis associated with blocking agents against tumor necrosis factor-alpha California, 2002-2003. MMWR Morb Mortal Wkly Rep. 2004;53:683.

Seong SS, Choi CB, Woo JH, Bae KW, Joung CL, Uhm WS, et al. Incidence of tuberculosis in Korean patients with rheumatoid arthritis (RA): effects of RA itself Rheumatol. 2007;34:706.

Gomez-ReinoJJ, Carmona L, Valverde VR, Mola EM, Montero MD. Treatment of rheumatoid arthritis with tumor necrosis factor Inhibitors may predispose to significant increase in tuberculosis risk: a multicenter active-surveillance report. Arthritis Rheum 2003;48:2122.

Furst DE, Keystone EC, So AK, Braun J, Breedveld FC, Burmester GR.

Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2012. Ann Rheum Dis. 2013;72 (Suppl 2).

Singh JA, Furst DE, Bharat A, Curtis JR, Kavanaugh AF, Kremer JM. 2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken). 2012;64:625.

Hatzara C, Hadziyannis E, Kandili A, Koutsianas C, Makris A, Georgiopoulos G. Frequent conversion of tuberculosis screening test during anti-tumour necrosis factor therapy in patients with rheumatic diseases. Ann Rheum Dis. 2014;0:1.

Park JH, Seo GY, Lee JS, Kim TH, Yoo DH. Positive conversion of tuberculin skin test and performance of interferón reléase assay to detect hidden tuberculosis infection during anti-tumor necrosis factor agent trial. J Rheum. 2009;10:1.

Cagatay T, Kilicaslan Z, Cagatay P, Mertsoylu M, Gulbaran Z, Yildiz R. TNF-alpha antagonist therapy modify the tuberculin skin test response. Rheumatol Int. 2011;9:147.

American Thoracic Society. Diagnosis Standards and Classification of Tuberculosis in Adults and Children. Am J Respir Crit Care Med. 2000;161:1376.

Ponce de León D, Acevedo-Vásquez E, Sánchez-Torres A, Cucho M, Alfaro J, Perich R, et al. Attenuated response to purified protein derivative in patients with rheumatoid arthritis: study in a population with a high prevalence of tuberculosis. Ann Rheum Dis. 2005;64:1360.


Métricas de artículo

Vistas de resumen

Cargando métricas ...

Enlaces refback

  • No hay ningún enlace refback.

Asociación Colombiana de Neumología y Cirugía de Tórax.
Dirección: Carrera 7 Bis # 123-52 Of. 202, Teléfono: 57(1)3222335 - Bogotá - Colombia.
Sistema OJS - Metabiblioteca |